HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Touchon, J. Articles by Gauthier, S. Search for Related Content PubMed PubMed Citation Articles by Touchon, J. Articles by Gauthier, S.

Neurology supplements are not peer-reviewed. Information contained in Neurology supplements represent the opinions of the authors and are not endorsed by nor do they reflect the views of the American Academy of Neurology, Editor-in-Chief, or Associate Editors of Neurology.

Prevention trials in Alzheimer disease

One step forward?

From the Neurology Service, Guy de Chauliac Hospital, Montpellier, France (J.T., F.P), INSERM E361, Montpellier University I, Pathologies of the Nervous System: Epidemiologic and Clinical Research, La Colombiera Hospital, Montpellier, France (J.T., F.P.), and McGill Centre for Studies in Aging, McGill University, Montreal, Canada (S.G.).

Address correspondence to Dr. Jacques Touchon, Centre Memoire de Ressource et de Recherche, Service de Neurologie, CHU Guy de Chauliac, 80 rue Auguste Fliche, 34295 Montpellier cedex 05, France; e-mail: jacques.touchon{at}wanadoo.fr

Finding strategies that prevent or delay the onset of dementia in Alzheimer disease (AD) will be a challenge for the years to come. Prevention trials in AD pose several unresolved questions, including methodologic, scientific, medical, regulatory, and ethical issues. A critical concern is the benefit and relative risk of giving a treatment to non-demented patients or to asymptomatic subjects. Some trials are under way and will perhaps move the field of prevention of dementia one big step forward.

Publication of this supplement was supported by an educational grant from Beaufour Ipsen.

Disclosure: The sponsor has provided J.T. with honoraria during his career.

This article has been cited by other articles:

				R. Remington, A. Chan, J. Paskavitz, and T. B. Shea Efficacy of a Vitamin/Nutriceutical Formulation for Moderate-stage to Later-stage Alzheimer's disease: A Placebo-controlled Pilot Study American Journal of Alzheimer's Disease and Other Dementias, February 1, 2009; 24(1): 27 - 33. [Abstract] [PDF]

				A. Chan, J. Paskavitz, R. Remington, S. Rasmussen, and T. B. Shea Efficacy of a Vitamin/Nutriceutical Formulation for Early-stage Alzheimer's Disease: A 1-year, Open-label Pilot Study With an 16-Month Caregiver Extension American Journal of Alzheimer's Disease and Other Dementias, January 1, 2009; 23(6): 571 - 585. [Abstract] [PDF]